EPITOPIC GmbH, founded in 2016 in Leipzig Germany, is the result of 4 years of collaboration between PolyQuant GmbH in Bad Abbach and the Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Leipzig, Germany. EPITOPIC and IZI have cross licensed essential technologies.
The exploitation of the broad application range of our technologies has just begun with epitope fingerprinting of antibodies. At IZI the research on the immunome’s response to vaccines, infectious disease agents or allergens is exploited in international research efforts. New business areas regarding immunome characterization will be added to EPITOPIC’s portfolio soon.
Header – highlighted epitope sequence (S)IYTSDnyxeE of anti-mouse CD184 antibody/CXCR4 (BD Pharmingen, Nr. 551966) in CD184 structure